Premières applications de la pharmacogénomique en oncologie. Stratégies industrielles et enjeux de régulation publique

Valerie Seror (valerie.seror@inserm.fr), Karim Elasri and Eric Avenel

Revue d'économie industrielle, 2007, vol. n° 120, issue 4, 13-13

Abstract: The present paper aims to analyze industrial strategies (involving biotechnology and pharmaceutical firms) in the context of oncology where the toxicity of chemotherapies used for cancer management make the development of pharmacogenomic testing particularly relevant, considering the possibility of drug prescriptions based on the results of genomic testing. Analysing the strategies that may be considered by the firms in this case of complementary goods illustrates how regulation may be used for industrial strategy purposes, and shows the impact on diffusion of pricing decisions made by the regulation agencies.

Keywords: Industrial Strategies; Complementary Goods; Regulation; Pharmacogenomics (search for similar items in EconPapers)
Date: 2007
References: Add references at CitEc
Citations:

Downloads: (external link)
http://www.cairn.info/load_pdf.php?ID_ARTICLE=REI_120_0013 (application/pdf)
http://www.cairn.info/revue-d-economie-industrielle-2007-4-page-13.htm (text/html)
free

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cai:reidbu:rei_120_0013

Access Statistics for this article

More articles in Revue d'économie industrielle from De Boeck Université
Bibliographic data for series maintained by Jean-Baptiste de Vathaire (operations@cairn.info).